ReviewMolecular neurobiology2026
Potential Role of Mitochondria-Associated Endoplasmic Reticulum Membranes (MAMs) Abnormalities in Epileptogenesis: Multimodal Mechanisms and Therapeutic Targets.
Review in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy is a prevalent neurological disorder characterized by an incompletely understood etiology and a substantial unmet therapeutic need, particularly for drug-resistant forms. This review examines the potential role of mitochondria-associated endoplasmic reticulum membranes (MAMs) as emerging signaling hubs in epileptogenesis. We systematically analyze how MAMs regulate core cellular processes-including calcium signaling, lipid metabolism, mitochondrial dynamics, autophagy, and oxidative stress-and how dysregulation of these processes may contribute to seizure initiation and progression. Furthermore, we evaluate existing interventions, such as phytotherapeutics and the ketogenic diet, from the perspective of modulation of MAMs. The review also highlights novel strategies targeting MAMs, including small-molecule approaches, nanodelivery systems, and neuromodulation technologies, which offer promising avenues for precise therapeutic intervention. By consolidating current molecular and genetic evidence, we identify MAMs as a critical hub in epilepsy and propose that targeting their integrity and function may represent a strategy to overcome drug resistance and modify disease progression. By integrating current knowledge of MAMs biology with epilepsy pathophysiology, this work provides a mechanistic framework to guide future research. It offers insights for the development of targeted molecular therapies for epilepsy.
Indexed as
Identifiers
42665778What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.